FMP
ESSA Pharma Inc.
EPIX
NASDAQ
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
6.25 USD
-0.15 (-2.4%)
About
ceo
Dr. David Ross Parkinson M.D.
sector
Healthcare
industry
Biotechnology
website
https://www.essapharma.com
exchange
NASDAQ
Description
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
CIK
0001633932
ISIN
CA29668H7085
CUSIP
29668H708
Address
999 West Broadway
Phone
17783310962
Country
CA
Employee
50
IPO Date
Mar 13, 2015
Summary
CIK
0001633932
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
29668H708
ISIN
CA29668H7085
Country
CA
Price
6.25
Beta
1.69
Volume Avg.
135.3k
Market Cap
276.49M
Shares
-
52-Week
2.56-11.67
DCF
0.76
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-10.59
P/B
-
Website
https://www.essapharma.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest EPIX News
It looks like there's no news available.
